Loading...
XHKG
2348
Market cap233mUSD
May 30, Last price  
1.22HKD
Name

Dawnrays Pharmaceutical (Holdings) Ltd

Chart & Performance

D1W1MN
No data to show
P/E
2.98
P/S
1.59
EPS
0.38
Div Yield, %
6.56%
Shrs. gr., 5y
-0.90%
Rev. gr., 5y
2.22%
Revenues
1.06b
-7.89%
734,002,000788,797,000919,945,000947,710,0001,082,110,0001,286,683,0001,081,044,000856,539,000914,973,000783,803,000985,000,000824,351,000882,483,000948,938,000950,007,0001,024,270,0001,165,155,0001,277,682,0001,151,145,0001,060,309,000
Net income
565m
+73.29%
105,704,00065,878,000101,157,000102,037,000118,388,000166,840,000146,307,000114,506,000153,099,000205,145,000302,198,000265,917,000292,978,000303,960,000255,430,000268,130,000358,175,000358,057,000326,000,000564,940,000
CFO
0k
-100.00%
34,489,00050,613,000130,551,00097,799,000138,987,000252,344,00082,986,000203,624,000231,262,000377,798,000298,322,000320,258,000390,741,000274,294,000275,837,000302,903,000393,139,000434,266,000338,400,0000
Dividend
Sep 16, 20240.015 HKD/sh

Profile

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.
URL
https://www.dawnrays.com/
IPO date
Jul 11, 2003
Employees
1,132
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,060,309
-7.89%
1,151,145
-9.90%
1,277,682
9.66%
Cost of revenue
857,285
860,689
855,273
Unusual Expense (Income)
NOPBT
203,024
290,456
422,409
NOPBT Margin
19.15%
25.23%
33.06%
Operating Taxes
74,187
91,390
82,557
Tax Rate
36.54%
31.46%
19.54%
NOPAT
128,837
199,066
339,852
Net income
564,940
73.29%
326,000
-8.95%
358,057
-0.03%
Dividends
(117,078)
(99,543)
Dividend yield
7.42%
4.98%
Proceeds from repurchase of equity
1,172
439
BB yield
-0.07%
-0.02%
Debt
Debt current
31,024
120,424
7,968
Long-term debt
8,550
570
2,422
Deferred revenue
300
Other long-term liabilities
124,310
Net debt
(1,345,822)
(804,832)
(1,096,791)
Cash flow
Cash from operating activities
338,400
434,266
CAPEX
(199,553)
(204,365)
Cash from investing activities
(387,573)
(175,013)
Cash from financing activities
2,070
(92,701)
FCF
(34,000)
121,099
395,754
Balance
Cash
1,365,396
1,066,697
1,081,836
Long term investments
20,000
(140,871)
25,345
Excess cash
1,332,381
868,269
1,043,297
Stockholders' equity
3,326,668
2,254,649
2,546,781
Invested Capital
2,153,316
2,111,492
1,606,632
ROIC
6.04%
10.71%
20.48%
ROCE
5.82%
9.45%
15.42%
EV
Common stock shares outstanding
1,505,897
1,502,602
1,502,310
Price
1.22
16.19%
1.05
-21.05%
1.33
-20.36%
Market cap
1,837,194
16.45%
1,577,732
-21.04%
1,998,072
-20.65%
EV
493,772
777,478
909,192
EBITDA
203,024
374,349
486,799
EV/EBITDA
2.43
2.08
1.87
Interest
989
371
Interest/NOPBT
0.34%
0.09%